What is NDC 63323-884?

63323-884 is the product NDC for Sodium Phosphates, Sodium phosphate, Monobasic, Monohydrate 276 mg/mL; Sodium phosphate, Dibasic, Anhydrous 142 mg/mL injection, solution, listed with the FDA by Fresenius Kabi USA, LLC. It has 1 package NDC, shown above in 10- and 11-digit form.

What drug is associated with this NDC?

Sodium Phosphates (Sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic, anhydrous).

What is the active ingredient?

Sodium phosphate, Monobasic, Monohydrate, Sodium phosphate, Dibasic, Anhydrous.

Fresenius Kabi USA, LLC, NDC labeler code 63323. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Sodium Phosphates?

14 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Sodium Phosphates NDC 63323-884 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)63323-884Labeler and product segments. Claims need a package NDC.

Product NDC at billing width63323-0884Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
63323-884-06	63323088406	25 VIAL, SINGLE-DOSE in 1 TRAY (63323-884-06) / 5 mL in 1 VIAL, SINGLE-DOSE (63323-884-01)Marketed from Mar 30, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Sodium Phosphates
Generic name (nonproprietary): sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic, anhydrous
Active ingredients: Sodium phosphate, Monobasic, Monohydrate — 276 mg/mLSodium phosphate, Dibasic, Anhydrous — 142 mg/mL
Dosage form: Injection, Solution
Route: Intravenous
Labeler: Fresenius Kabi USA, LLCNDC labeler code 63323
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 209997
Marketing start: Mar 30, 2022
Listing expires: Dec 31, 2026
Other FDA classes: Increased Large Intestinal Motility (Physiologic effect)Inhibition Large Intestine Fluid/Electrolyte Absorption (Physiologic effect)Osmotic Activity (Mechanism)
Identifiers: Product ID 63323-884_3ae3c9a3-3503-4264-8c77-00089f50cc74SPL ID 3ae3c9a3-3503-4264-8c77-00089f50cc74SPL set ID 5bf47be3-f3fe-452b-8113-941796498345RxCUI 1872384, 1872443, 1872447UNII 22ADO53M6F, 593YOG76RN
Pharmacologic class: Osmotic Laxative

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N463323088406 followed by a unit qualifier and the quantity

Package 63323-0884-06. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 31, 2022.

Indications (excerpt from the label)

INDICATIONS AND USAGE: Sodium Phosphates Injection, USP, 3 mM P/mL is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific parenteral fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. The concomitant amount of sodium (Na + 4 mEq/mL) must be calculated into total electrolyte dose of such prepared solutions.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 63323-884

What is NDC 63323-884?: 63323-884 is the product NDC for Sodium Phosphates, Sodium phosphate, Monobasic, Monohydrate 276 mg/mL; Sodium phosphate, Dibasic, Anhydrous 142 mg/mL injection, solution, listed with the FDA by Fresenius Kabi USA, LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Sodium Phosphates (Sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic, anhydrous).
What is the active ingredient?: Sodium phosphate, Monobasic, Monohydrate, Sodium phosphate, Dibasic, Anhydrous.
Who is the labeler?: Fresenius Kabi USA, LLC, NDC labeler code 63323. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Sodium Phosphates?: 14 other product NDCs are listed under this name. See all Sodium Phosphates NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Sodium Phosphates NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Sodium Phosphates	Sodium phosphate, Monobasic, Monohydrate 276 mg/mL; Sodium phosphate, Dibasic, Heptahydrate 268 mg/mL	Injection, SolutionIntravenous	Caplin Steriles Limited	65145-200	65145-0200-25
Sodium Phosphates	Sodium phosphate, Monobasic, Monohydrate 276 mg/mL; Sodium phosphate, Dibasic, Heptahydrate 268 mg/mL	Injection, SolutionIntravenous	Caplin Steriles Limited	65145-201	65145-0201-25
Sodium Phosphates	Sodium phosphate, Monobasic, Monohydrate 276 mg/mL; Sodium phosphate, Dibasic, Heptahydrate 268 mg/mL	Injection, SolutionIntravenous	Caplin Steriles Limited	65145-202	65145-0202-25
Sodium Phosphates	Sodium phosphate, Monobasic, Monohydrate 276 mg/mL; Sodium phosphate, Dibasic, Heptahydrate 268 mg/mL	Injection, SolutionIntravenous	GLENMARK PHARMACEUTICALS INC., USA	68462-728	68462-0728-25
Sodium Phosphates	Sodium phosphate, Monobasic, Monohydrate 276 mg/mL; Sodium phosphate, Dibasic, Heptahydrate 268 mg/mL	Injection, SolutionIntravenous	GLENMARK PHARMACEUTICALS INC., USA	68462-729	68462-0729-25
Sodium Phosphates	Sodium phosphate, Monobasic, Monohydrate 276 mg/mL; Sodium phosphate, Dibasic, Heptahydrate 268 mg/mL	Injection, SolutionIntravenous	GLENMARK PHARMACEUTICALS INC., USA	68462-730	68462-0730-25
Sodium Phosphatessodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic anhydrous	Sodium phosphate, Monobasic, Monohydrate 276 mg/mL; Sodium phosphate, Dibasic, Anhydrous 142 mg/mL	Injection, SolutionIntravenous	Civica, Inc.	72572-309	72572-0309-25
Sodium Phosphatessodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic anhydrous	Sodium phosphate, Monobasic, Monohydrate 276 mg/mL; Sodium phosphate, Dibasic, Anhydrous 142 mg/mL	Injection, SolutionIntravenous	American Regent, Inc.	0517-7350	00517-7350-25
Sodium Phosphatessodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic anhydrous	Sodium phosphate, Monobasic, Monohydrate 276 mg/mL; Sodium phosphate, Dibasic, Anhydrous 142 mg/mL	Injection, SolutionIntravenous	American Regent, Inc.	0517-7305	00517-7305-25
Sodium Phosphatessodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic anhydrous	Sodium phosphate, Monobasic, Monohydrate 276 mg/mL; Sodium phosphate, Dibasic, Anhydrous 142 mg/mL	Injection, SolutionIntravenous	American Regent, Inc.	0517-7315	00517-7315-25

All 15 Sodium Phosphates NDCs

Other NDCs under ANDA 209997

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 209997
Product	Strength	Form · route	Labeler	Product NDC
Sodium Phosphatessodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic, anhydrous	Sodium phosphate, Monobasic, Monohydrate 276 mg/mL; Sodium phosphate, Dibasic, Anhydrous 142 mg/mL	Injection, SolutionIntravenous	Fresenius Kabi USA, LLC	63323-881
Sodium Phosphatessodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic, anhydrous	Sodium phosphate, Monobasic, Monohydrate 276 mg/mL; Sodium phosphate, Dibasic, Anhydrous 142 mg/mL	Injection, SolutionIntravenous	Fresenius Kabi USA, LLC	63323-886